Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:MDIT NASDAQ:OBLN NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDITCytoCore$0.00$0.00▼$0.00N/A108.54N/AN/AOBLNObalon Therapeutics$2.13+0.9%$4.22$0.66▼$10.77$21.35M-1.237.68 million shs12,576 shsPSTVPlus Therapeutics$3.98$5.44$2.90▼$23.42$27.40M1.4217,285 shs223,168 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDITCytoCore0.00%0.00%0.00%0.00%0.00%OBLNObalon Therapeutics0.00%0.00%0.00%0.00%-12.35%PSTVPlus Therapeutics-4.33%-6.57%-27.24%+11.80%-48.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDITCytoCore$0.00$0.00▼$0.00N/A108.54N/AN/AOBLNObalon Therapeutics$2.13+0.9%$4.22$0.66▼$10.77$21.35M-1.237.68 million shs12,576 shsPSTVPlus Therapeutics$3.98$5.44$2.90▼$23.42$27.40M1.4217,285 shs223,168 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDITCytoCore0.00%0.00%0.00%0.00%0.00%OBLNObalon Therapeutics0.00%0.00%0.00%0.00%-12.35%PSTVPlus Therapeutics-4.33%-6.57%-27.24%+11.80%-48.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDITCytoCore 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/APSTVPlus Therapeutics 2.43Hold$56.401,317.09% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, OBLN, and MDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.004/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDITCytoCoreN/AN/AN/AN/AN/AN/AOBLNObalon Therapeutics$1.59M13.43N/AN/A$0.60 per share3.55PSTVPlus Therapeutics$5.21M5.26N/AN/A$0.72 per share5.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDITCytoCoreN/AN/AN/AN/AN/AN/AN/AN/AN/AOBLNObalon Therapeutics-$12.33MN/AN/AN/AN/A-776.76%-161.38%-83.58%N/APSTVPlus Therapeutics-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)Latest PSTV, OBLN, and MDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PSTVPlus Therapeutics-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMDITCytoCoreN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDITCytoCoreN/AN/AN/AOBLNObalon TherapeuticsN/A1.861.86PSTVPlus TherapeuticsN/A2.272.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDITCytoCoreN/AOBLNObalon Therapeutics18.64%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipMDITCytoCore85.40%OBLNObalon Therapeutics8.10%PSTVPlus Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDITCytoCore71N/AN/ANot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionablePSTVPlus Therapeutics206.88 million6.71 millionNot OptionablePSTV, OBLN, and MDIT HeadlinesRecent News About These CompaniesPlus Therapeutics Inc.July 2 at 1:31 AM | barrons.comPlus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)June 30 at 1:55 PM | finance.yahoo.comPlus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy TranscriptJune 30 at 1:00 PM | seekingalpha.comPlus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial ProgressJune 30 at 7:51 AM | quiverquant.comQPlus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingJune 30 at 7:30 AM | globenewswire.comPlus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration AssayJune 25, 2026 | quiverquant.comQPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerJune 25, 2026 | globenewswire.comPlus Therapeutics to Provide Business Update Call on June 30, 2026June 23, 2026 | globenewswire.comPlus Therapeutics Launches New At-The-Market Equity ProgramJune 5, 2026 | tipranks.comPlus Therapeutics gains CAP accreditation for CNSide CSF assay platformJune 4, 2026 | proactiveinvestors.comCNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical LaboratoryJune 4, 2026 | quiverquant.comQPlus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical LaboratoryJune 4, 2026 | globenewswire.comPlus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual MeetingMay 26, 2026 | quiverquant.comQPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal MetastasesMay 26, 2026 | globenewswire.comPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyMay 19, 2026 | globenewswire.comPlus Therapeutics Stockholders Back Directors and Incentive PlanMay 15, 2026 | tipranks.comPlus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comPlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial RolloutMay 15, 2026 | globenewswire.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6May 14, 2026 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)May 14, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, OBLN, and MDIT Company DescriptionsCytoCore OTCMKTS:MDITMedite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Plus Therapeutics NASDAQ:PSTV$3.98 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.98 +0.00 (+0.13%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
